Sponsor pipeline

Immutep S.A.S. clinical trial pipeline

Get alerts when Immutep S.A.S.'s trials change

2 active trials 1 recruiting 1 Phase 3 2 disease areas 6 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-07-31
Trial terminated
Trial terminated: Sponsor Decision
Primary endpoint(s) modified
Enrollment reduced: 849 → 72 participants
Primary completion moved earlier: 2026-10-31 → 2026-04-30
Completion moved earlier: 2027-07-31 → 2026-06-30
NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in… · Phase 2/3

Active trials by phase

Phase 1
1
Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT06726265 Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy… Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Active, Not Recruiting 2026-03-18
Phase 1
NCT06637865 A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy… Healthy Recruiting 2026-04-23

Disease areas by active trials

Non-Small Cell Lung Cancer (NSCLC) (1) · Lung Cancer (1)

Get alerts when Immutep S.A.S.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free